384 related articles for article (PubMed ID: 34937871)
1. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.
Vos JL; Elbers JBW; Krijgsman O; Traets JJH; Qiao X; van der Leun AM; Lubeck Y; Seignette IM; Smit LA; Willems SM; van den Brekel MWM; Dirven R; Baris Karakullukcu M; Karssemakers L; Klop WMC; Lohuis PJFM; Schreuder WH; Smeele LE; van der Velden LA; Bing Tan I; Onderwater S; Jasperse B; Vogel WV; Al-Mamgani A; Keijser A; van der Noort V; Broeks A; Hooijberg E; Peeper DS; Schumacher TN; Blank CU; de Boer JP; Haanen JBAG; Zuur CL
Nat Commun; 2021 Dec; 12(1):7348. PubMed ID: 34937871
[TBL] [Abstract][Full Text] [Related]
2. [
Vos JL; Zuur CL; Smit LA; de Boer JP; Al-Mamgani A; van den Brekel MWM; Haanen JBAG; Vogel WV
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2010-2022. PubMed ID: 34957526
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.
Schoenfeld JD; Hanna GJ; Jo VY; Rawal B; Chen YH; Catalano PS; Lako A; Ciantra Z; Weirather JL; Criscitiello S; Luoma A; Chau N; Lorch J; Kass JI; Annino D; Goguen L; Desai A; Ross B; Shah HJ; Jacene HA; Margalit DN; Tishler RB; Wucherpfennig KW; Rodig SJ; Uppaluri R; Haddad RI
JAMA Oncol; 2020 Oct; 6(10):1563-1570. PubMed ID: 32852531
[TBL] [Abstract][Full Text] [Related]
5. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.
Ferrarotto R; Amit M; Nagarajan P; Rubin ML; Yuan Y; Bell D; El-Naggar AK; Johnson JM; Morrison WH; Rosenthal DI; Glisson BS; Johnson FM; Lu C; Mott FE; Esmaeli B; Diaz EM; Gidley PW; Goepfert RP; Lewis CM; Weber RS; Wargo JA; Basu S; Duan F; Yadav SS; Sharma P; Allison JP; Myers JN; Gross ND
Clin Cancer Res; 2021 Aug; 27(16):4557-4565. PubMed ID: 34187851
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
Ferris RL; Spanos WC; Leidner R; Gonçalves A; Martens UM; Kyi C; Sharfman W; Chung CH; Devriese LA; Gauthier H; Chiosea SI; Vujanovic L; Taube JM; Stein JE; Li J; Li B; Chen T; Barrows A; Topalian SL
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083421
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck.
Johnson JM; Vathiotis IA; Harshyne LA; Ali A; Bar Ad V; Axelrod R; Lorber E; Curry J; Cognetti DM; Luginbuhl AJ; Tuluc M; Keith S; Mahoney MG; Argiris A
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37536941
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck.
Hanna GJ; O'Neill A; Shin KY; Wong K; Jo VY; Quinn CT; Cutler JM; Flynn M; Lizotte PH; Annino DJ; Goguen LA; Kass JI; Rettig EM; Sethi RKV; Lorch JH; Schoenfeld JD; Margalit DN; Tishler RB; Everett PC; Desai AM; Cavanaugh ME; Paweletz CP; Egloff AM; Uppaluri R; Haddad RI
Clin Cancer Res; 2022 Feb; 28(3):468-478. PubMed ID: 34667025
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
Cascone T; Leung CH; Weissferdt A; Pataer A; Carter BW; Godoy MCB; Feldman H; William WN; Xi Y; Basu S; Sun JJ; Yadav SS; Rojas Alvarez FR; Lee Y; Mishra AK; Chen L; Pradhan M; Guo H; Sinjab A; Zhou N; Negrao MV; Le X; Gay CM; Tsao AS; Byers LA; Altan M; Glisson BS; Fossella FV; Elamin YY; Blumenschein G; Zhang J; Skoulidis F; Wu J; Mehran RJ; Rice DC; Walsh GL; Hofstetter WL; Rajaram R; Antonoff MB; Fujimoto J; Solis LM; Parra ER; Haymaker C; Wistuba II; Swisher SG; Vaporciyan AA; Lin HY; Wang J; Gibbons DL; Jack Lee J; Ajami NJ; Wargo JA; Allison JP; Sharma P; Kadara H; Heymach JV; Sepesi B
Nat Med; 2023 Mar; 29(3):593-604. PubMed ID: 36928818
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.
Reuss JE; Anagnostou V; Cottrell TR; Smith KN; Verde F; Zahurak M; Lanis M; Murray JC; Chan HY; McCarthy C; Wang D; White JR; Yang S; Battafarano R; Broderick S; Bush E; Brock M; Ha J; Jones D; Merghoub T; Taube J; Velculescu VE; Rosner G; Illei P; Pardoll DM; Topalian S; Naidoo J; Levy B; Hellmann M; Brahmer JR; Chaft JE; Forde PM
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929052
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial.
Huang X; Liu Q; Zhong G; Peng Y; Liu Y; Liang L; Hong H; Feng W; Yang S; Zhang Y; Xian S; Li Z; Zhou Y; Zhang Z; Jiang W; Liang J; Liu ZG
J Exp Clin Cancer Res; 2022 Oct; 41(1):300. PubMed ID: 36224603
[TBL] [Abstract][Full Text] [Related]
12. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
Motzer RJ; Escudier B; McDermott DF; Arén Frontera O; Melichar B; Powles T; Donskov F; Plimack ER; Barthélémy P; Hammers HJ; George S; Grünwald V; Porta C; Neiman V; Ravaud A; Choueiri TK; Rini BI; Salman P; Kollmannsberger CK; Tykodi SS; Grimm MO; Gurney H; Leibowitz-Amit R; Geertsen PF; Amin A; Tomita Y; McHenry MB; Saggi SS; Tannir NM
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661118
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Diffusion-Weighted Imaging Analyses to Predict Response to Neoadjuvant Immunotherapy in Patients with Locally Advanced Head and Neck Carcinoma.
van der Hulst HJ; Vos JL; Tissier R; Smit LA; Martens RM; Beets-Tan RGH; van den Brekel MWM; Zuur CL; Castelijns JA
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551718
[TBL] [Abstract][Full Text] [Related]
14. Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504.
Gillison ML; Ferris RL; Harris J; Colevas AD; Mell LK; Kong C; Jordan RC; Moore KL; Truong MT; Kirsch C; Chakravarti A; Blakaj DM; Clump DA; Ohr JP; Deeken JF; Gensheimer MF; Saba NF; Dorth JA; Rosenthal DI; Leidner RS; Kimple RJ; Machtay M; Curran WJ; Torres-Saavedra P; Le QT
Int J Radiat Oncol Biol Phys; 2023 Mar; 115(4):847-860. PubMed ID: 36228746
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Cascone T; William WN; Weissferdt A; Leung CH; Lin HY; Pataer A; Godoy MCB; Carter BW; Federico L; Reuben A; Khan MAW; Dejima H; Francisco-Cruz A; Parra ER; Solis LM; Fujimoto J; Tran HT; Kalhor N; Fossella FV; Mott FE; Tsao AS; Blumenschein G; Le X; Zhang J; Skoulidis F; Kurie JM; Altan M; Lu C; Glisson BS; Byers LA; Elamin YY; Mehran RJ; Rice DC; Walsh GL; Hofstetter WL; Roth JA; Antonoff MB; Kadara H; Haymaker C; Bernatchez C; Ajami NJ; Jenq RR; Sharma P; Allison JP; Futreal A; Wargo JA; Wistuba II; Swisher SG; Lee JJ; Gibbons DL; Vaporciyan AA; Heymach JV; Sepesi B
Nat Med; 2021 Mar; 27(3):504-514. PubMed ID: 33603241
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint blockade induced shifts in cytokine expression patterns in peripheral blood of head and neck cancer patients are linked to outcome.
Röhl L; Wellhausen J; Berszin M; Krücken I; Zebralla V; Pirlich M; Wiegand S; Dietz A; Wald T; Wichmann G
Front Immunol; 2023; 14():1237623. PubMed ID: 37849764
[TBL] [Abstract][Full Text] [Related]
17. Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma.
Okamoto I; Tsukahara K; Sato H
Sci Rep; 2022 Feb; 12(1):2025. PubMed ID: 35132165
[TBL] [Abstract][Full Text] [Related]
18. Predictive capacity of immune-related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma.
Alnemri AE; Tekumalla S; Moroco AE; Vathiotis I; Tuluc M; Gargano S; Zhan T; Cognetti DM; Curry JM; Argiris A; Linnenbach A; South AP; Harshyne LA; Johnson JM; Luginbuhl AJ
Cancer Med; 2024 Jun; 13(11):e7370. PubMed ID: 38847087
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Haddad R; Concha-Benavente F; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Kasper S; Vokes EE; Worden F; Saba NF; Tahara M; Jayaprakash V; Lynch M; Li L; Gillison ML; Harrington KJ; Ferris RL
Cancer; 2019 Sep; 125(18):3208-3218. PubMed ID: 31246283
[TBL] [Abstract][Full Text] [Related]
20. Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.
Zech HB; Moeckelmann N; Boettcher A; Muenscher A; Binder M; Vettorazzi E; Bokemeyer C; Schafhausen P; Betz CS; Busch CJ
Future Oncol; 2020 Dec; 16(36):3035-3043. PubMed ID: 32902312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
